CSL Limited (ASX:CSL) is a global biotechnology company operating through CSL Behring, CSL Vifor and CSL Seqirus. FY26 marked a significant reset for the group, combining broadly stable underlying Earnings with substantial restructuring and Impairment charges that resulted in a statutory loss. The company's FY27 outlook now places greater emphasis on cost reductions, divisional execution and the performance of its core plasma therapies business.

FY26 Results Reflect a Significant Accounting Reset

For the year ended 30 June 2026, CSL reported Revenue of US$15.797 billion, representing growth of 2 per cent on a reported basis but a decline of 1 per cent in constant currency.

Underlying net profit after tax and amortisation, or NPATA, was US$3.098 billion, compared with US$3.219 billion in FY25. NPATA is an underlying earnings measure that excludes certain Amortisation and other items to provide a view of operational profitability.

The statutory result differed sharply from the underlying result. CSL recorded a net loss of US$2.579 billion for FY26, compared with a statutory profit of US$3.002 billion in FY25.

The loss reflected substantial restructuring and impairment charges. After-tax restructuring and impairment expenses totalled US$5.416 billion, while pre-tax impairments were approximately US$7.1 billion. The difference between these figures reflects their different accounting bases rather than conflicting measures.

The impairment programme included significant write-downs associated with CSL Vifor, as well as charges linked to the Lengnau Manufacturing Facility and self-amplifying mRNA intellectual property.

CSL Behring Remains the Group's Largest Business

CSL Behring continued to account for the majority of group revenue in FY26, contributing approximately 72 per cent of the total.

The division develops and commercialises plasma-derived therapies, including immunoglobulins, albumin and treatments for bleeding disorders. Immunoglobulin sales were US$6.2 billion and were broadly flat over FY26, although growth improved to 7 per cent during the second half.

The second-half improvement provides an important operating indicator heading into FY27 because CSL Behring remains the group's primary earnings engine.

Albumin sales, however, declined by 17 per cent, reflecting cost-containment measures in China. This makes Demand conditions in the Chinese market an important Factor for the division's performance during the new financial year.

For FY27, CSL expects CSL Behring to deliver mid-single-digit revenue growth, placing the division at the centre of the group's expected earnings progression.

CSL Vifor Faces a More Difficult FY27

CSL Vifor specialises in treatments for iron deficiency and nephrology. The division was also associated with a significant portion of the impairment charges recognised during FY26.

The Business enters FY27 facing a materially different revenue outlook. CSL expects Vifor revenue to decline by approximately 25 per cent during the year.

Competitive pressure across iron-related products is one of the major operating factors affecting the division. Against this backdrop, the ability to manage the business through the expected revenue contraction while implementing broader restructuring measures will be an important consideration in FY27.

The impairment charges also indicate that management has reassessed the carrying value of Assets and expectations associated with parts of the Vifor portfolio.

CSL Seqirus Remains Under Strategic Review

CSL Seqirus, the group's influenza Vaccine business, reported FY26 revenue of US$2.0 billion, down 8 per cent. Seasonal influenza vaccine sales nevertheless increased by 4 per cent.

CSL had previously considered separating Seqirus through a demerger, but the proposed transaction has been deferred while the company undertakes a further assessment of market conditions.

The deferral means Seqirus remains part of the broader CSL portfolio while management evaluates its strategic options.

The division's future structure therefore remains one of the key corporate developments to monitor alongside its underlying operating performance.

Cost Savings Become Central to FY27 Execution

CSL realised US$176 million of cost savings during FY26 and is targeting approximately US$400 million of savings in FY27.

The restructuring programme is designed to simplify operations and improve the group's cost base. Longer term, the company is targeting approximately US$550 million in savings by FY28.

Achieving these targets will require successful implementation across multiple parts of the organisation. Cost reductions can support profitability, but their financial impact will depend on the timing of delivery and the extent to which savings are sustained.

CSL also expects approximately US$200 million of additional charges in FY27 as the restructuring programme continues.

Balance Sheet and Capital Returns Remain Relevant

Operating cash flow was approximately US$3.5 billion in FY26, while net Debt stood at US$9.3 billion, equivalent to around 1.8 times EBITDA.

CSL completed an A$1 billion share buy-back and subsequently authorised a further programme of A$1.1 billion.

The company also declared a final Dividend of US$1.62 per security, unfranked, with a Record Date of 2 October 2026. Together with the US$1.30 Interim Dividend paid in April 2026, total FY26 dividends amounted to US$2.92 per security.

These capital management measures are taking place while CSL continues to fund restructuring initiatives and manage its existing debt position.

FY27 Guidance Sets a Modest Growth Benchmark

For FY27, CSL expects group revenue to be broadly in line with FY26 on a constant-currency basis while underlying net profit is expected to increase by approximately 5 per cent.

The guidance reflects different expectations across CSL's businesses. CSL Behring is expected to produce mid-single-digit growth, while CSL Vifor is expected to record a significant revenue decline.

The group therefore enters FY27 with underlying earnings growth expected to depend partly on improved operational efficiency and cost savings rather than substantial consolidated revenue expansion.

Currency movements will remain relevant because CSL generates earnings across multiple international markets and reports its financial results in US dollars.

Key Risks and Areas to Monitor

The scale of the FY26 impairments places renewed attention on capital allocation and the expected returns from assets that have been written down. Additional restructuring charges expected in FY27 mean the financial effects of the reset are not yet fully complete.

CSL Vifor's expected revenue contraction presents another operational challenge, while Chinese albumin demand remains important for CSL Behring.

Leadership transition is also relevant, with Gordon Naylor serving as interim chief executive. The appointment of a permanent chief executive will therefore be an important corporate milestone.

Execution of the cost-reduction programme will also be closely watched. The increase in targeted savings from US$176 million delivered in FY26 to approximately US$400 million in FY27 requires a significant step-up in implementation.

What Comes Next for CSL Limited (ASX:CSL)?

The first major test of the FY27 outlook will be the half-year period ending 31 December 2026. That result should provide further evidence on CSL Behring's growth trajectory, the anticipated contraction at CSL Vifor and progress against the group's restructuring programme.

CSL's Annual General Meeting is scheduled for 27 October 2026 in Melbourne, while the final dividend record date falls on 2 October 2026.

Further developments around a permanent chief executive appointment and the strategic assessment of CSL Seqirus will also remain relevant. After the substantial accounting reset recorded in FY26, the focus in FY27 shifts toward operational delivery, cost savings and the group's ability to produce the underlying earnings growth outlined in its guidance.